Oncology
Palleon’s lead program, E-602, is a first-in-class engineered human genetic fusion from Palleon’s EAGLE platform. The EAGLE (Enzyme-Antibody Glyco-Ligand Editing) platform enables creation of novel biological therapeutics by genetic fusion of human sialidase with human monoclonal antibodies. E-602 is designed to desialylate both immune cells and tumor cells.
HER2-Sialidase is a novel glyco-immunology therapeutic from Palleon’s EAGLE platform. The EAGLE (Enzyme-Antibody Glyco-Ligand Editing) platform enables creation of novel biological therapeutics by genetic fusion of human sialidase with human monoclonal antibodies. HER2-Sialidase is designed to target HER2-expressing tumors to enhance the desialylation of tumor cells. These molecules also retain their HER2-mediated anti-tumor activity. Both HER2-low and HER2-high expressing tumors can be treated with this therapy.
In June 2022 Palleon entered into a strategic collaboration with Henlius to co-develop HER2-Sialidase. Under the terms of the agreement, Palleon will perform research and the parties will then share preclinical and global clinical development responsibilities and costs for HER2-Sialidase. Henlius has an exclusive license to HER2-Sialidase in Greater China, while Palleon retains all other global rights.
PD-L1-Sialidase is a novel glyco-immunology therapeutic from Palleon’s EAGLE platform. The EAGLE (Enzyme-Antibody Glyco-Ligand Editing) platform enables creation of novel biological therapeutics by genetic fusion of human sialidase with human monoclonal antibodies. PD-L1-Sialidase is designed to target PD-L1-expressing tumors and immune cells to enhance the desialylation of both tumor cells and immune cells. These molecules also block PD1/PD-L1 interaction.
